Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes
Bernhard K. Krämer, Christoph Wanner(Universitätsklinikum Würzburg), Johannes F.E. Mann(Katholische Stiftungshochschule München), David Fitchett(McGill University), Dominik Steubl(Boehringer Ingelheim (Germany)), Michaela Mattheus(Boehringer Ingelheim (Germany)), Robert Ćhilton(The University of Texas at San Antonio Health Science Center), Sibylle J. Hauske(Heidelberg University), Lars Gullestad(Oslo University Hospital)
Cited by 6
Related Papers
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Rosuvastatin in Older Patients with Systolic Heart Failure
|New England Journal of Medicine|2007|1.5k
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
|New England Journal of Medicine|2024|1.5k